Cell and Gene Therapy for Musculoskeletal Diseases Market Research Report – Segmentation By Disease Type (Osteoarthritis, Rheumatoid Arthritis, Bone Fracture, Osteoporosis, Others); By Gene Type (Bone Morphogenetic Protein (BMP), Fibroblast Growth Factor (FGF), Transforming Growth Factor-Beta (TGF-β), Platelet-Derived Growth Factor (PDGF), Others); By Vector Type (Retroviral Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Plasmid DNA Vector, Others); and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-14969
Format:
Region: Global
Chapter 1. CELL AND GENE THERAPY FOR MUSCULOSKELETAL DISEASES MARKET – Scope & Methodology
1.1. Market Segmentation
1.2. Assumptions
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. CELL AND GENE THERAPY FOR MUSCULOSKELETAL DISEASES MARKET – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.3. COVID-19 Impact Analysis
2.3.1. Impact during 2023 – 2030
2.3.2. Impact on Supply – Demand
Chapter 3. CELL AND GENE THERAPY FOR MUSCULOSKELETAL DISEASES MARKET – Competition Scenario
3.1. Market Share Analysis
3.2. Product Benchmarking
3.3. Competitive Strategy & Development Scenario
3.4. Competitive Pricing Analysis
3.5. Supplier - Distributor Analysis
Chapter 4. CELL AND GENE THERAPY FOR MUSCULOSKELETAL DISEASES MARKET - Entry Scenario
4.1. Case Studies – Start-up/Thriving Companies
4.2. Regulatory Scenario - By Region
4.3 Customer Analysis
4.4. Porter's Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. CELL AND GENE THERAPY FOR MUSCULOSKELETAL DISEASES MARKET - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. CELL AND GENE THERAPY FOR MUSCULOSKELETAL DISEASES MARKET – by Disease type
6.1. Osteoarthritis
6.2. Rheumatoid Arthritis
6.3. Bone Fracture
6.4. Osteoporosis
6.5. Others
Chapter 7. CELL AND GENE THERAPY FOR MUSCULOSKELETAL DISEASES MARKET – By Gene Type
7.1. Bone Morphogenetic Protein (BMP)
7.2. Fibroblast Growth Factor (FGF)
7.3. Transforming Growth Factor-Beta (TGF-β)
7.4. Platelet-Derived Growth Factor (PDGF)
7.5. Others
Chapter 8. CELL AND GENE THERAPY FOR MUSCULOSKELETAL DISEASES MARKET – By Vector Type
8.1. Retroviral Vector
8.2. Adenoviral Vector
8.3. Adeno-Associated Viral Vector
8.4. Lentiviral Vector
8.5. Plasmid DNA Vector
8.6. Others
Chapter 9. CELL AND GENE THERAPY FOR MUSCULOSKELETAL DISEASES MARKET – By Region
9.1. North America
9.2. Europe
9.3.The Asia Pacific
9.4.Latin America
9.5. Middle-East and Africa
Chapter 10. CELL AND GENE THERAPY FOR MUSCULOSKELETAL DISEASES MARKET– Company Profiles – (Overview, Product Portfolio, Financials, Developments)
10.1. Mesoblast Ltd.
10.2. TiGenix NV
10.3. Vericel Corporation
10.4. Osiris Therapeutics, Inc.
10.5. Stryker Corporation
10.6. Zimmer Biomet Holdings, Inc.
10.7. Medipost Co., Ltd.
10.8. RTI Surgical Holdings, Inc.
10.9. CollPlant Biotechnologies Ltd.
10.10. Orthocell Ltd.
Download Sample
Choose License Type
2850
5250
4500
1800
Frequently Asked Questions
Cell and gene therapy for musculoskeletal diseases is a new approach to treating these conditions using cellular and genetic materials to repair or replace damaged tissues and cells
Cell and gene therapy is currently being researched for a range of musculoskeletal diseases, including osteoarthritis, rheumatoid arthritis, muscular dystrophy, and spinal cord injuries
The potential benefits of cell and gene therapy for musculoskeletal diseases include improved pain relief, reduced inflammation, enhanced tissue repair, and the potential for a long-term cure.
Like any medical procedure, there are risks associated with cell and gene therapy for musculoskeletal diseases. These can include infections, immune reactions, and other complications.
While research into cell and gene therapy for musculoskeletal diseases is ongoing, these treatments are still in the early stages of development and are not widely available to patients at this time. However, as research progresses, it is possible that these therapies will become more widely available in the future.
